Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644972 | 1.00 | JAK3 (0.41) | JAK3EGFRKRASMAPK14ROCK2 | |
| SCHEMBL30622380 | 0.92 | JAK3 (0.40) | JAK3EGFRBMXBTKITK | |
| SCHEMBL26645119 | 0.92 | JAK3 (0.40) | JAK3EGFRBMXBTKITK | |
| SCHEMBL30622348 | 0.87 | BTK (0.35) | JAK3EGFRKRASROCK2LIMK1 | |
| SCHEMBL26644847 | 0.87 | BTK (0.35) | JAK3EGFRKRASROCK2LIMK1 | |
| SCHEMBL26645123 | 0.85 | MAPK14 (0.46) | JAK3EGFRMAPK14ROCK1BMX | |
| SCHEMBL30622366 | 0.85 | MAPK14 (0.46) | JAK3EGFRMAPK14ROCK1BMX | |
| SCHEMBL30622386 | 0.83 | JAK3 (0.41) | JAK3EGFRKRASMAPK14ROCK2 | |
| SCHEMBL30622303 | 0.83 | JAK3 (0.41) | JAK3EGFRKRASMAPK14ROCK2 | |
| SCHEMBL26645276 | 0.83 | JAK3 (0.41) | JAK3EGFRKRASMAPK14ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |